financetom
Business
financetom
/
Business
/
Tata Power completes sale of its defence biz to Tata Advanced Systems
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tata Power completes sale of its defence biz to Tata Advanced Systems
Nov 2, 2020 4:39 AM

Tata Power on Monday said it has completed the sale of its defence business to Tata Advanced Systems. Tata Advanced Systems is a wholly-owned subsidiary of Tata Sons. ”The sale was completed as per a Scheme of Arrangement, which was approved by the National Company Law Tribunal at Mumbai and Hyderabad in December 2019 and March 2020, respectively,” Tata Power said in a regulatory filing. The company said it is expected to receive an enterprise value of Rs 1,076 crore as an upfront payment.

Balance consideration is subject to completion of achieving certain milestones specified in the agreements, the company added. Tata Power said the sale of defence business is part of the company’s ongoing strategic plan to monetise its non-core assets and reduce overall leverage.

”The sale proceeds will help the company to reduce leverage and increase focus in the core business areas like renewable generation, distribution and new service-led businesses which will bring greater value for our shareholders,” Praveer Sinha, CEO and Managing Director, Tata Power said. Strategic Engineering Division (SED) is a non-core defence electronics division of the company, engaged in business of indigenous design, development, production, integration, supply and life cycle support of mission-critical defence systems.

The key products include manufacturing and assembling missile launchers, electronic warfare, night vision systems and gun systems. SED has three dedicated manufacturing units — Bangalore Electronic City, Vemagal in Karnataka (under construction) and an SEZ near Bengaluru (under construction).

First Published:Nov 2, 2020 1:39 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Nauticus Robotics to Acquire SeaTrepid International
Nauticus Robotics to Acquire SeaTrepid International
Mar 6, 2025
04:01 AM EST, 03/06/2025 (MT Newswires) -- Nauticus Robotics ( KITT ) said late Wednesday it has agreed to acquire SeaTrepid International, a provider of underwater robotic services. Financial terms were not disclosed. The company said the merged entity's revenue is expected to be around nine times higher than Nauticus' 2024 revenue. The acquisition is expected to close in May,...
Bread Financial Prices $400 Million Subordinated Notes Offering
Bread Financial Prices $400 Million Subordinated Notes Offering
Mar 6, 2025
04:09 AM EST, 03/06/2025 (MT Newswires) -- Bread Financial Holdings ( BFH ) said late Wednesday it priced a $400 million offering of of 8.375% fixed-rate reset subordinated notes due 2035 at 100% of the principal amount. The notes issuance is expected to close on March 10 and result in about $395 million of net proceeds for the company, it...
Aquestive Therapeutics Q4 Net Loss Widens, Revenue Falls; 2025 Revenue Outlook Issued
Aquestive Therapeutics Q4 Net Loss Widens, Revenue Falls; 2025 Revenue Outlook Issued
Mar 6, 2025
03:57 AM EST, 03/06/2025 (MT Newswires) -- Aquestive Therapeutics ( AQST ) reported Q4 net loss Wednesday of $0.19 per share, widening from a loss of $0.12 a year earlier. Two analysts polled by FactSet expected a loss of $0.14. Revenue for the quarter ended Dec. 31 was $11.9 million, down from $13.2 million a year earlier. Analysts surveyed by...
QIAGEN Gets US FDA Clearance for Second QIAstat-Dx Mini Gastrointestinal Panel
QIAGEN Gets US FDA Clearance for Second QIAstat-Dx Mini Gastrointestinal Panel
Mar 6, 2025
04:03 AM EST, 03/06/2025 (MT Newswires) -- QIAGEN NV ( QGEN ) said Thursday that the US Food and Drug Administration has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, marking the company's second FDA clearance of a QIAstat-Dx panel in 2025. The company said it has now received regulatory clearances for three mini panels for the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved